Artwork

Content provided by Hopkins Biotech Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Hopkins Biotech Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer

38:56
 
Distribuie
 

Manage episode 351985331 series 2788785
Content provided by Hopkins Biotech Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Hopkins Biotech Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial.

Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions at public and private biotechs including Centocor, Bristol Myers Squibb, and the Liposome Company. He earned his MBA at Northwestern University’s Kellogg School of Business.

In this episode, we discuss cell cycle dysregulation in cancer, precision targeting of proteins in the drug design process, and unique clinical trial design.

Hosted by Joe Varriale.

  continue reading

84 episoade

Artwork
iconDistribuie
 
Manage episode 351985331 series 2788785
Content provided by Hopkins Biotech Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Hopkins Biotech Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial.

Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positions at public and private biotechs including Centocor, Bristol Myers Squibb, and the Liposome Company. He earned his MBA at Northwestern University’s Kellogg School of Business.

In this episode, we discuss cell cycle dysregulation in cancer, precision targeting of proteins in the drug design process, and unique clinical trial design.

Hosted by Joe Varriale.

  continue reading

84 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință

Listen to this show while you explore
Play